Pallas Capital Advisors LLC Makes New Investment in CVS Health Corporation $CVS

Pallas Capital Advisors LLC bought a new position in CVS Health Corporation (NYSE:CVS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 15,805 shares of the pharmacy operator’s stock, valued at approximately $1,635,000.

A number of other large investors have also modified their holdings of CVS. Deutsche Bank AG purchased a new stake in shares of CVS Health during the 2nd quarter valued at about $466,634,000. Perigon Wealth Management LLC purchased a new position in CVS Health in the 2nd quarter worth approximately $3,536,000. Commerzbank Aktiengesellschaft FI acquired a new stake in CVS Health in the second quarter valued at approximately $8,212,000. Trust Co. of Vermont acquired a new stake in CVS Health in the second quarter valued at approximately $2,979,000. Finally, Principle Wealth Partners LLC purchased a new stake in shares of CVS Health during the second quarter valued at approximately $2,143,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Buying and Selling

In other CVS Health news, Director Larry Robbins sold 1,018,000 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $93.82, for a total transaction of $95,508,760.00. Following the completion of the sale, the director owned 5,195,261 shares in the company, valued at $487,419,387.02. The trade was a 16.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is currently owned by corporate insiders.

CVS Health Stock Down 3.3%

NYSE:CVS opened at $93.99 on Tuesday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The company has a market capitalization of $120.21 billion, a price-to-earnings ratio of 24.87, a price-to-earnings-growth ratio of 0.93 and a beta of 0.61. CVS Health Corporation has a one year low of $69.40 and a one year high of $110.68. The stock has a 50-day simple moving average of $102.46 and a 200 day simple moving average of $88.41.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. The firm had revenue of $106.10 billion for the quarter, compared to analysts’ expectations of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.CVS Health’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Sell-side analysts predict that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were paid a dividend of $0.665 per share. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 annualized dividend and a yield of 2.8%. CVS Health’s dividend payout ratio (DPR) is 70.37%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CVS shares. Argus raised their price target on shares of CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a report on Thursday, May 14th. Barclays boosted their price objective on shares of CVS Health from $106.00 to $108.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. UBS Group raised their target price on CVS Health from $122.00 to $126.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Piper Sandler reaffirmed an “overweight” rating and set a $113.00 target price on shares of CVS Health in a research report on Monday, June 1st. Finally, Bank of America boosted their price target on CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Twenty-two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $106.75.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.